Stockreport

Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]

Werewolf Therapeutics, Inc.  (HOWL) 
PDF US$0.40 loss per share (further deteriorated from US$0.14 loss in 2Q 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Werewolf [Read more]